Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AV024 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Monovalent vaccine prior to the release of the trivalent vaccine (FluMist). |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AV024 | BIOLOGICAL | 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril). |
| Placebo | OTHER | Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril). |
Inclusion Criteria: * 18-64 years of age (not yet reached their 65th birthday); * In good health; * Available by telephone; * Ability to understand and comply with the requirements of the protocol; and * Signed informed consent. Exclusion Criteria: * Any condition, other than age, for which the i...
AV024 is a monoclonal antibody being developed for influenza. It is currently in Phase 3 clinical development as an investigational therapy. The drug is being studied for its safety and efficacy in treating or preventing influenza, a viral infection that affects the respiratory system.
AV024 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of AV024 for the treatment of influenza.
AV024 is currently in Phase 3 clinical development. This is the final stage of testing before a potential regulatory submission. The drug is being evaluated in a Phase 3 clinical trial to assess its safety and efficacy in patients with influenza. It is not yet approved by regulatory authorities.
AV024 has one completed Phase 3 clinical trial with the identifier NCT00240877. This study evaluated the safety of a monovalent vaccine of a new 6:2 reassortant in healthy adults. The trial enrolled 330 participants in the United States and was a randomized, double-blind, placebo-controlled study.
AV024 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The drug is being studied for the treatment of influenza, but it has not yet received regulatory approval. The completed Phase 3 trial evaluated its safety in healthy adults.